Therapeutic lipid target achievements among high and highest risk patients: Results from the CEPHEUS study in the Arabian Gulf

Khalid Al-Rasadi, Ibrahim Al-Zakwani, Wael Al Mahmeed, Mohamed Arafah, Ali T. Al-Hinai, Abdullah Shehab, Omer Al Tamimi, Mahmoud Alawadhi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: To determine lipid target achievements of low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apo B) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS) in Arabian Gulf States patients with high and highest risk according to the joint Consensus Statement of the American Diabetes Association (ADA) and American College of Cardiology Foundation (ACC).

Methods: CEPHEUS was conducted in patients (≥18 years of age) in six Middle Eastern countries between November 2009 and July 2010 on lipid lowering drugs (LLDs). Serum samples collected included total cholesterol (TC), LDL-C, HDL-C, triglycerides (TGs), apo B, and apolipoprotein A1 (apo A1).

Results: The overall mean age of the cohort (n=5275) was 56±13 years, 58% (n=3060) were male and 69% (n=3635) were highest risk. LDL-C target was achieved in 25%, non-HDL-C in 36% and apo B in 38% of patients in the highest risk cohort compared with LDL-C 46%, non-HDL-C 58% and apo B 51% in the high risk group. In patients with TGs ≥2.2 mmol/L, LDL-C target was achieved in 16% and apo B in 15% of patients in the highest risk group compared with LDL-C 32% and apo B 22% in the high risk cohort.

Conclusion: Despite being on LLDs, a large proportion of high and highest risk patients in the Arabian Gulf are not at recommended lipid targets and remain at a substantial residual risk for cardiovascular diseases. Apo B may be used as an additional target in patients with triglycerides ≥2.2 mmol/L. The findings should be interpreted in light of the study's limitations.

Original languageEnglish
Pages (from-to)2429-2435
Number of pages7
JournalCurrent Medical Research and Opinion
Volume30
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

LDL Cholesterol
Apolipoproteins B
Lipids
Triglycerides
Therapeutics
Middle East
Apolipoprotein A-I
Hypercholesterolemia
Pharmaceutical Preparations
Consensus
Cardiovascular Diseases
Joints
Cholesterol
Serum
lipoprotein cholesterol

Keywords

  • Apolipoprotein B
  • Arabs
  • Cardiovascular disease
  • Low density lipoprotein cholesterol
  • Middle East
  • Triglycerides

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapeutic lipid target achievements among high and highest risk patients : Results from the CEPHEUS study in the Arabian Gulf. / Al-Rasadi, Khalid; Al-Zakwani, Ibrahim; Al Mahmeed, Wael; Arafah, Mohamed; Al-Hinai, Ali T.; Shehab, Abdullah; Al Tamimi, Omer; Alawadhi, Mahmoud.

In: Current Medical Research and Opinion, Vol. 30, No. 12, 01.12.2014, p. 2429-2435.

Research output: Contribution to journalArticle

Al-Rasadi, Khalid ; Al-Zakwani, Ibrahim ; Al Mahmeed, Wael ; Arafah, Mohamed ; Al-Hinai, Ali T. ; Shehab, Abdullah ; Al Tamimi, Omer ; Alawadhi, Mahmoud. / Therapeutic lipid target achievements among high and highest risk patients : Results from the CEPHEUS study in the Arabian Gulf. In: Current Medical Research and Opinion. 2014 ; Vol. 30, No. 12. pp. 2429-2435.
@article{022ff5ac097f407e8e4f9b0db194508c,
title = "Therapeutic lipid target achievements among high and highest risk patients: Results from the CEPHEUS study in the Arabian Gulf",
abstract = "Objective: To determine lipid target achievements of low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apo B) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS) in Arabian Gulf States patients with high and highest risk according to the joint Consensus Statement of the American Diabetes Association (ADA) and American College of Cardiology Foundation (ACC).Methods: CEPHEUS was conducted in patients (≥18 years of age) in six Middle Eastern countries between November 2009 and July 2010 on lipid lowering drugs (LLDs). Serum samples collected included total cholesterol (TC), LDL-C, HDL-C, triglycerides (TGs), apo B, and apolipoprotein A1 (apo A1).Results: The overall mean age of the cohort (n=5275) was 56±13 years, 58{\%} (n=3060) were male and 69{\%} (n=3635) were highest risk. LDL-C target was achieved in 25{\%}, non-HDL-C in 36{\%} and apo B in 38{\%} of patients in the highest risk cohort compared with LDL-C 46{\%}, non-HDL-C 58{\%} and apo B 51{\%} in the high risk group. In patients with TGs ≥2.2 mmol/L, LDL-C target was achieved in 16{\%} and apo B in 15{\%} of patients in the highest risk group compared with LDL-C 32{\%} and apo B 22{\%} in the high risk cohort.Conclusion: Despite being on LLDs, a large proportion of high and highest risk patients in the Arabian Gulf are not at recommended lipid targets and remain at a substantial residual risk for cardiovascular diseases. Apo B may be used as an additional target in patients with triglycerides ≥2.2 mmol/L. The findings should be interpreted in light of the study's limitations.",
keywords = "Apolipoprotein B, Arabs, Cardiovascular disease, Low density lipoprotein cholesterol, Middle East, Triglycerides",
author = "Khalid Al-Rasadi and Ibrahim Al-Zakwani and {Al Mahmeed}, Wael and Mohamed Arafah and Al-Hinai, {Ali T.} and Abdullah Shehab and {Al Tamimi}, Omer and Mahmoud Alawadhi",
year = "2014",
month = "12",
day = "1",
doi = "10.1185/03007995.2014.965774",
language = "English",
volume = "30",
pages = "2429--2435",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Therapeutic lipid target achievements among high and highest risk patients

T2 - Results from the CEPHEUS study in the Arabian Gulf

AU - Al-Rasadi, Khalid

AU - Al-Zakwani, Ibrahim

AU - Al Mahmeed, Wael

AU - Arafah, Mohamed

AU - Al-Hinai, Ali T.

AU - Shehab, Abdullah

AU - Al Tamimi, Omer

AU - Alawadhi, Mahmoud

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Objective: To determine lipid target achievements of low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apo B) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS) in Arabian Gulf States patients with high and highest risk according to the joint Consensus Statement of the American Diabetes Association (ADA) and American College of Cardiology Foundation (ACC).Methods: CEPHEUS was conducted in patients (≥18 years of age) in six Middle Eastern countries between November 2009 and July 2010 on lipid lowering drugs (LLDs). Serum samples collected included total cholesterol (TC), LDL-C, HDL-C, triglycerides (TGs), apo B, and apolipoprotein A1 (apo A1).Results: The overall mean age of the cohort (n=5275) was 56±13 years, 58% (n=3060) were male and 69% (n=3635) were highest risk. LDL-C target was achieved in 25%, non-HDL-C in 36% and apo B in 38% of patients in the highest risk cohort compared with LDL-C 46%, non-HDL-C 58% and apo B 51% in the high risk group. In patients with TGs ≥2.2 mmol/L, LDL-C target was achieved in 16% and apo B in 15% of patients in the highest risk group compared with LDL-C 32% and apo B 22% in the high risk cohort.Conclusion: Despite being on LLDs, a large proportion of high and highest risk patients in the Arabian Gulf are not at recommended lipid targets and remain at a substantial residual risk for cardiovascular diseases. Apo B may be used as an additional target in patients with triglycerides ≥2.2 mmol/L. The findings should be interpreted in light of the study's limitations.

AB - Objective: To determine lipid target achievements of low-density lipoprotein cholesterol (LDL-C), non-high density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (apo B) in the Centralized Pan-Middle East Survey on the undertreatment of hypercholesterolemia (CEPHEUS) in Arabian Gulf States patients with high and highest risk according to the joint Consensus Statement of the American Diabetes Association (ADA) and American College of Cardiology Foundation (ACC).Methods: CEPHEUS was conducted in patients (≥18 years of age) in six Middle Eastern countries between November 2009 and July 2010 on lipid lowering drugs (LLDs). Serum samples collected included total cholesterol (TC), LDL-C, HDL-C, triglycerides (TGs), apo B, and apolipoprotein A1 (apo A1).Results: The overall mean age of the cohort (n=5275) was 56±13 years, 58% (n=3060) were male and 69% (n=3635) were highest risk. LDL-C target was achieved in 25%, non-HDL-C in 36% and apo B in 38% of patients in the highest risk cohort compared with LDL-C 46%, non-HDL-C 58% and apo B 51% in the high risk group. In patients with TGs ≥2.2 mmol/L, LDL-C target was achieved in 16% and apo B in 15% of patients in the highest risk group compared with LDL-C 32% and apo B 22% in the high risk cohort.Conclusion: Despite being on LLDs, a large proportion of high and highest risk patients in the Arabian Gulf are not at recommended lipid targets and remain at a substantial residual risk for cardiovascular diseases. Apo B may be used as an additional target in patients with triglycerides ≥2.2 mmol/L. The findings should be interpreted in light of the study's limitations.

KW - Apolipoprotein B

KW - Arabs

KW - Cardiovascular disease

KW - Low density lipoprotein cholesterol

KW - Middle East

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=84914150237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84914150237&partnerID=8YFLogxK

U2 - 10.1185/03007995.2014.965774

DO - 10.1185/03007995.2014.965774

M3 - Article

C2 - 25222765

AN - SCOPUS:84914150237

VL - 30

SP - 2429

EP - 2435

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 12

ER -